Aeglea Bio Therapeutics (AGLE) Receiving Somewhat Favorable Press Coverage, Report Shows

News stories about Aeglea Bio Therapeutics (NASDAQ:AGLE) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.4036102128865 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Separately, Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th.

Aeglea Bio Therapeutics (AGLE) traded up $0.44 during mid-day trading on Tuesday, hitting $5.89. 38,200 shares of the company’s stock were exchanged, compared to its average volume of 81,967. Aeglea Bio Therapeutics has a 12-month low of $2.81 and a 12-month high of $8.14. The stock has a market capitalization of $99.35 and a PE ratio of -3.22.

In other news, CFO Charles N. York II acquired 6,500 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were purchased at an average price of $4.59 per share, for a total transaction of $29,835.00. Following the completion of the transaction, the chief financial officer now owns 10,828 shares of the company’s stock, valued at $49,700.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Anthony G. Quinn acquired 7,956 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was purchased at an average price of $4.98 per share, for a total transaction of $39,620.88. Following the transaction, the director now directly owns 14,100 shares of the company’s stock, valued at approximately $70,218. The disclosure for this purchase can be found here. Insiders acquired 57,691 shares of company stock worth $269,483 in the last 90 days. Corporate insiders own 27.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply